Greenwich LifeSciences (GLSI) announced its partnership with clinical sites in Italy. The company has partnered with “Gruppo Italiano Mammella” – GIM -, the largest academic cooperative breast cancer research group in Italy, including over 150 participating centers and approximately 500 investigators, with 28 clinical trials on-going today. Breast cancer is the leading cause of death from cancer in women in Italy with 15,455 deaths in 2022. Nine of the top enrolling institutions belonging to GIM have agreed to participate in its Phase III clinical trial, FLAMINGO-01.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI: